{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:51:53Z","timestamp":1793886713890,"version":"4.8.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To observe the effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome(PCOS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 64 overweight\/obese women with PCOS diagnosed <jats:italic>via<\/jats:italic> the Rotterdam criteria were randomly assigned to metformin(MET) 850 mg twice a day(BID) or combined MET 850 mg BID with beinaglutide (COMB) starting at 0.1mg three times a day(TID)and increasing to 0.2mg TID two weeks later. The main endpoints were changes in anthropometric measurements of obesity. Glucose and lipid metabolic, gonadal profiles, and antral follicle count changes as secondary outcomes were also observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>60(93.75%) patients completed the study. In terms of lowering weight, body mass index (BMI),waist circumference(WC) and waist to height ratio(WHtR), COMB treatment outperformed MET monotherapy. Subjects in the COMB arm lost weight 4.54\u00b13.16kg compared with a 2.47\u00b13.59kg loss in the MET arm. In the COMB group, BMI,WC and WHtR were reduced significantly compared with that in the MET group, respectively. COMB therapy is also more favorable in the reduction of fasting insulin(FINS), total testosterone(TT), and homeostasis model assessment\u2013insulin resistance(HOMA-IR) when compared to MET therapy. Antral follicle count and ovarian volume were non-significantly changed in both groups.The most frequent side effects in both groups were mild and moderate digestive symptoms. Itching and induration at the injection site were reported with COMB treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.chictr.org.cn\/listbycreater.aspx<\/jats:ext-link>, identifier ChiCTR2000033741.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1156521","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T20:46:22Z","timestamp":1686084382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Qing","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiding","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2014.00140","article-title":"The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study","volume":"5","author":"Rasmussen","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.3390\/ijms23084334","article-title":"The role of glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome","volume":"23","author":"Bednarz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMcp1514916","article-title":"Polycystic ovary syndrome","volume":"375","author":"McCartney","year":"2016","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.04.046","article-title":"Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS)","volume":"228","author":"Li","year":"2019","journal-title":"Life Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmv025","article-title":"Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis","volume":"21","author":"Naderpoor","year":"2015","journal-title":"Hum Reprod Update"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0797","article-title":"Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin","volume":"170","author":"Jensterle Sever","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"103382","DOI":"10.1016\/j.isci.2021.103382","article-title":"Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice","volume":"24","author":"Zhang","year":"2021","journal-title":"iScience"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Elkind-Hirsch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491","article-title":"Exenatide plus metformin compared with metformin alone on \u03b2-cell function in patients with type 2 diabetes","volume":"29","author":"Derosa","year":"2012","journal-title":"Diabet. Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3109\/07435800","article-title":"Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome","volume":"40","author":"Jensterle","year":"2015","journal-title":"Endocr. Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.342","article-title":"Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study","volume":"5","author":"Zhang","year":"2019","journal-title":"Obes Sci Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00163-2","article-title":"Polycystic ovary syndrome. the lancet","volume":"10","author":"Joham","year":"2022","journal-title":"Diabetes Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertil. Steril"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2437","article-title":"Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline","volume":"93","author":"Martin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmig.2018.01.036","article-title":"Impact of ultrasound-guided transvaginal ovarian needle drilling versus laparoscopic ovarian drilling on ovarian reserve and pregnancy rate in polycystic ovary syndrome: a randomized clinical trial","volume":"25","author":"Kandil","year":"2018","journal-title":"J Minim. Invasive Gynecol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(90)90005-M","article-title":"Power and sample size calculations. a review and computer program","volume":"11","author":"Dupont","year":"1990","journal-title":"Control. Clin Trials"},{"key":"B20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40261-020-00942-2","article-title":"Liraglutide: new perspectives for the treatment of polycystic ovary syndrome","volume":"40","author":"Papaetis","year":"2020","journal-title":"Clin Drug Investig"},{"key":"B21","doi-asserted-by":"publisher","first-page":"118966","DOI":"10.1016\/j.lfs.2020.118966","article-title":"Beinaglutide shows significantly beneficial effects in diabetes\/obesity-induced nonalcoholic steatohepatitis in ob\/ob mouse model","volume":"270","author":"Fang","year":"2021","journal-title":"Life Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916038","article-title":"Controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3945\/jn.114.206029","article-title":"Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling","volume":"145","author":"Ronveaux","year":"2015","journal-title":"J Nutr"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00520.2015","article-title":"GLP-1 and weight loss: unraveling the diverse neural circuitry","volume":"310","author":"Kanoski","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn","article-title":"Polycystic ovary syndrome in adolescents","volume":"48","author":"Rothenberg","year":"2018","journal-title":"Best Pract Res Clin Obstet. Gynaecol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.11.002","article-title":"Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics","volume":"92","author":"Glueck","year":"2019","journal-title":"Metabolism"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001712","article-title":"Short-term combined treatment with exenatide and metformin for overweight\/obese women with polycystic ovary syndrome","volume":"134","author":"Ma","year":"2021","journal-title":"Chin Med J (Engl.)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.945609","article-title":"Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome","volume":"13","author":"Xing","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"Controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.149","article-title":"Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults","volume":"38","author":"Lean","year":"2014","journal-title":"Int J Obes (Lond.)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin Sci (Lond.)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1937-z","article-title":"Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-\u03b1 in mice","volume":"54","author":"Maida","year":"2011","journal-title":"Diabetologia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment","volume":"14","author":"Escobar-Morreale","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab408","article-title":"Exenatide, dapagliflozin, or Phentermine\/Topiramate differentially affect metabolic profiles in polycystic ovary syndrome","volume":"106","author":"Elkind-Hirsch","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2019.04.017","article-title":"GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis","volume":"39","author":"Han","year":"2019","journal-title":"Reprod biomedicine Online"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study","volume":"179","author":"Salamun","year":"2018","journal-title":"Eur Soc Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3081","article-title":"Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: randomized control study","volume":"11","author":"Jensterle","year":"2016","journal-title":"Exp Ther Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13454","article-title":"Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome","volume":"87","author":"Liu","year":"2017","journal-title":"Clin Endocrinol (Oxf.)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew243","article-title":"Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies","volume":"31","author":"Cassar","year":"2016","journal-title":"Hum Reprod"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2017.03.023","article-title":"Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial","volume":"35","author":"Nylander","year":"2017","journal-title":"Reprod biomedicine Online"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/endo-121-3-1076","article-title":"Identification and localization of glucagon-like peptide-1 and its receptor in rat brain","volume":"121","author":"Shimizu","year":"1987","journal-title":"Endocrinology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","article-title":"Cellular and molecular mechanisms of metformin action","volume":"42","author":"LaMoia","year":"2021","journal-title":"Endocr. Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/nu13020351","article-title":"Incretin hormones in obesity and related cardiometabolic disorders: the clinical perspective","volume":"13","author":"Micha\u0142owska","year":"2021","journal-title":"Nutrients"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0751","article-title":"The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome","volume":"93","author":"Thomson","year":"2008","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1156521\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T20:46:24Z","timestamp":1686084384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1156521\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":48,"alternative-id":["10.3389\/fendo.2023.1156521"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1156521","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"article-number":"1156521"}}